CDK4 Inhibition and Doxorubicin Mediate Breast Cancer Cell Apoptosis Through Smad3 and Survivin

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2014 Jul 10

PMID 25006666

Citations 11

Authors

Elizabeth Tarasewicz

Randala Hamdan

Joelle Straehla

Ashley Hardy

Omar Nunez

Stanislav Zelivianski

Danijela Dokic

Jacqueline S Jeruss

Affiliations

Soon will be listed here.

Abstract

Cyclin D1/CDK4 activity is upregulated in up to 50% of breast cancers and CDK4-mediated phosphorylation negatively regulates the TGFβ superfamily member Smad3. We sought to determine if CDK4 inhibition and doxorubicin chemotherapy could impact Smad3-mediated cell/colony growth and apoptosis in breast cancer cells. Parental and cyclin D1-overexpressing MCF7 cells were treated with CDK4 inhibitor, doxorubicin, or combination therapy and cell proliferation, apoptosis, colony formation, and expression of apoptotic proteins were evaluated using an MTS assay, TUNEL staining, 3D Matrigel assay, and apoptosis array/immunoblotting. Study cells were also transduced with WT Smad3 or a Smad3 construct resistant to CDK4 phosphorylation (5M) and colony formation and expression of apoptotic proteins were assessed. Treatment with CDK4 inhibitor/doxorubicin combination therapy, or transduction with 5M Smad3, resulted in a similar decrease in colony formation. Treating cyclin D overexpressing breast cancer cells with combination therapy also resulted in the greatest increase in apoptosis, resulted in decreased expression of anti-apoptotic proteins survivin and XIAP, and impacted subcellular localization of pro-apoptotic Smac/DIABLO. Additionally, transduction of 5M Smad3 and doxorubicin treatment resulted in the greatest change in apoptotic protein expression. Collectively, this work showed the impact of CDK4 inhibitor-mediated, Smad3-regulated tumor suppression, which was augmented in doxorubicin-treated cyclin D-overexpressing study cells.

Citing Articles

Multiomic characterization, immunological and prognostic potential of SMAD3 in pan-cancer and validation in LIHC.

Zhou T, Zhang D, Jin J, Xie J, Yu J, Zhu C Sci Rep. 2025; 15(1):657.

PMID: 39753728 PMC: 11698864. DOI: 10.1038/s41598-024-84553-3.

Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.

Sritharan S, Guha S, Hazarika S, Sivalingam N Apoptosis. 2022; 27(9-10):622-646.

PMID: 35716277 DOI: 10.1007/s10495-022-01742-z.

Phosphorylation-Induced Ubiquitination and Degradation of PXR through CDK2-TRIM21 Axis.

Qin M, Xin Y, Bian Y, Yang X, Xi T, Xiong J Cells. 2022; 11(2).

PMID: 35053380 PMC: 8773821. DOI: 10.3390/cells11020264.

Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer.

Decker J, Ma J, Shea L, Jeruss J Cancers (Basel). 2021; 13(21).

PMID: 34771508 PMC: 8582459. DOI: 10.3390/cancers13215343.

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.

Padhye A, Konen J, Rodriguez B, Fradette J, Ochieng J, Diao L JCI Insight. 2021; 6(17).

PMID: 34309585 PMC: 8492319. DOI: 10.1172/jci.insight.148392.

References

Keyomarsi K, Pardee A . Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A. 1993; 90(3):1112-6. PMC: 45821. DOI: 10.1073/pnas.90.3.1112. View

Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S . Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res. 2007; 27(4C):2803-8. View

Pardali K, Kurisaki A, Moren A, Ten Dijke P, Kardassis D, Moustakas A . Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem. 2000; 275(38):29244-56. DOI: 10.1074/jbc.M909467199. View

Tarasewicz E, Jeruss J . Phospho-specific Smad3 signaling: impact on breast oncogenesis. Cell Cycle. 2012; 11(13):2443-51. PMC: 3404875. DOI: 10.4161/cc.20546. View

Mansour A, Nabil M, Ali-Labib R, Said H, Annos F . Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer. Med Oncol. 2011; 29(4):2535-42. DOI: 10.1007/s12032-011-0129-0. View

Bukholm I, Berner J, Nesland J, Borresen-Dale A . Expression of cyclin Ds in relation to p53 status in human breast carcinomas. Virchows Arch. 1998; 433(3):223-8. DOI: 10.1007/s004280050240. View

Cao Z, Zhang R, Li J, Huang H, Zhang D, Zhang J . X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis. J Biol Chem. 2013; 288(28):20238-47. PMC: 3711291. DOI: 10.1074/jbc.M112.448365. View

Zelivianski S, Cooley A, Kall R, Jeruss J . Cyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin D-overexpressing breast cancer cells. Mol Cancer Res. 2010; 8(10):1375-87. PMC: 3253857. DOI: 10.1158/1541-7786.MCR-09-0537. View

Li Y, Wang M, Carra C, Cucinotta F . Modularized Smad-regulated TGFβ signaling pathway. Math Biosci. 2012; 240(2):187-200. DOI: 10.1016/j.mbs.2012.07.005. View

10.

Shao J, Teraishi F, Katsuda K, Tanaka N, Fujiwara T . p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells. Biochem Biophys Res Commun. 2002; 290(3):1101-7. DOI: 10.1006/bbrc.2001.6314. View

11.

Buckley M, Sweeney K, Hamilton J, Sini R, Manning D, Nicholson R . Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993; 8(8):2127-33. View

12.

Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J . Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000; 96(5):1921-5. View

13.

Jeruss J, Sturgis C, Rademaker A, Woodruff T . Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res. 2003; 63(13):3783-90. View

14.

Aaltonen K, Amini R, Landberg G, Eerola H, Aittomaki K, Heikkila P . Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2008; 113(1):75-82. DOI: 10.1007/s10549-008-9908-5. View

15.

Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y . Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006; 9(1):23-32. DOI: 10.1016/j.ccr.2005.12.012. View

16.

Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C . Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994; 54(7):1812-7. View

17.

Sun B, Wingate H, Swisher S, Keyomarsi K, Hunt K . Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle. 2010; 9(6):1122-30. DOI: 10.4161/cc.9.6.10990. View

18.

Swana H, Grossman D, Anthony J, Weiss R, Altieri D . Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999; 341(6):452-3. DOI: 10.1056/NEJM199908053410614. View

19.

Xiong J, Hu L, Li Y, Dou L, Cai P, Tang Z . Effect of survivin regulation of transcription level by p21waf1 overexpression in HepG2 hepatocellular carcinoma cells. J Huazhong Univ Sci Technolog Med Sci. 2008; 28(3):308-13. DOI: 10.1007/s11596-008-0318-z. View

20.

Xing N, Qian J, Bostwick D, Bergstralh E, Young C . Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate. 2001; 48(1):7-15. DOI: 10.1002/pros.1076. View